AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06418347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole is an aromatase inhibitor that controls the conversion of androgen to estrogen and increases ovarian androgens. The administration of letrozole in the follicular phase removes the effect of negative estrogen feedback on the pituitary and hypothalamus, thus increasing the gonadotropins\]. When Letrozole blocks estrogen production, it encourages the body to produce more follicle-stimulating hormone (FSH).The additional FSH stimulates egg development and increases the likelihood of ovulation. Kar, S. Found that letrozole has excellent pregnancy rates compared to clomiphene citrate, Letrozole should be considered at par with clomiphene citrate as first-line drug for ovulation induction in infertile PCOS women.
Study NCT05198180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical 30%Potassium hydroxide solution
Description: Patients will apply the solution every day under occlusion for 3 months
Study NCT05198180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical 45% hydrogen peroxide solution
Description: Patients will apply the solution every day under occlusion
Study NCT04832022 — intervention group
Intervention type: OTHER
Intervention: Biological samples
Description: Serum and plasma samples. At baseline, 3, 6 and 12 months
Study NCT05858112 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SuperTROPO novel assay to measure the long forms of cTnT
Description: SuperTROPO novel assay to measure the long forms of cTnT
Study NCT04736134 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BMS-986326
Description: Specified dose on specified days
Study NCT04736134 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo matching BMS-986326
Description: Specified dose on specified days
Study NCT04736134 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multiple Ascending Dose SC
Description: Specified dose on specified days
Study NCT04736134 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Multiple Ascending Dose Placebo
Description: Specified dose on specified days
Study NCT04859452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DBPR108 tablets
Description: Drug: DBPR108, tablet, oral
Study NCT04859452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin hydrochloride tablets
Description: Drug: Metformin hydrochloride, tablet, oral
Study NCT04859452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glibenclamide tablets
Description: Drug: Glibenclamide, tablet, oral
Study NCT05097352 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Description: Twenty minutes of HIIT will be completed three days a week for six weeks.
Study NCT05097352 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Waitlist
Description: Waitlist participants will be tested on the outcomes at the same time points as the treatment group.
Study NCT04859452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan Capsules
Description: Drug: Valsartan, capsule, oral
Study NCT04859452 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin tablets
Description: Drug: Simvastatin, tablet, oral
Study NCT05955183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AZD5055
Description: AZD5055 will be given orally to randomized participants as per the arm they are assigned.
Study NCT05955183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AZD5055
Description: AZD5055 will be given orally to randomized participants as per the arm they are assigned.
Study NCT05955183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be given orally to randomized participants as per the arm they are assigned.
Study NCT05955183 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given orally to randomized participants as per the arm they are assigned.
Study NCT04447898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPV-06 10 μg
Description: Low dose + Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112
Study NCT04447898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPV-06 50 μg
Description: High dose+ Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112
Study NCT04447898 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo+ Montanide™ ISA 51 VG in SC administration = 3 injections on Day 0, Day 28, and Day 112
Study NCT06353698 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fasting mimicking diet
Description: Fasting mimicking diet is limited calorie diet to enhance the effectiveness of chemotherapy
Study NCT05568667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low risk
Description: * remote support in physical activity and nutrition via digital media~* monthly collective physical activity sessions~* logbook
Study NCT05568667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate risk
Description: * remote support in physical activity and nutrition via digital media~* monthly collective physical activity sessions~* one collective health education session~* logbook
Study NCT05568667 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High risk
Description: * remote support in physical activity and nutrition via digital media~* monthly collective physical activity sessions~* one collective health education session~* 3 individual sessions of motivational coaching~* connected watch~* logbook
Study NCT04966689 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: combined speech and music therapy
Description: he telerehabilitation intervention that include both speech therapy and music therapy at the same time
Study NCT04966689 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: speech therapy
Description: A behavioural speech therapy program including breathing exercises, loudness, pitch, and intelligibility which are adapted from Lee Silverman Voice Treatment (LSVT) and voice exercises Which is delivered through telerehabilitation
Study NCT04966689 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: music therapy
Description: music exercises Will be designed based on the music therapy protocols of previous studies Which is delivered through telerehabilitation
Study NCT03992092 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-MAC VS
Description: C-MAC Video Stylet
Study NCT03992092 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible Bronchoscopy
Description: Flexible Bronchoscopy
Study NCT06004570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Complex product
Description: Extracts from the fruits of Vaccinium myrtillus L. + Aronia Melanocarpa (Michx.) Elliot + Lonicera caerulea var. Kamtschatica, rutin, vitamin B6, vitamin B12, folic acid Single oral dose - 2 capsules
Study NCT06004570 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Polyphenol-rich extracts
Description: Extracts from the fruits of Vaccinium myrtillus L. + Aronia Melanocarpa (Michx.) Elliot + Lonicera caerulea var. Kamtschatica Single oral dose - 2 capsules
Study NCT06004570 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose - 2 capsules
Study NCT06065436 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Collagenase Clostridium Histolyticum
Description: Total of 8 Intralesional injection (0.90 mg), administered as four separate injection series. Within each series, subjects will receive two injections, administered approximately 1-7 days apart.
Study NCT06065436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collagenase Clostridium Histolyticum
Description: Total of 8 Intralesional injection (0.90 mg), administered as four separate injection series. Within each series, subjects will receive two injections, administered approximately 1-7 days apart.
Study NCT06065436 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Storz Duolith LiSWT
Description: Single low intensity shockwave therapy consistent of 1,500 shocks at a rate of 120 shocks/minute and using a power setting of 0.09 mJ/mm2. These treatments will occur four separate times, before each of the four separate CCH injection series.
Study NCT04958226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: Capivasertib (tablet) will be given as an intermittent schedule (4 days on/3 days off) from Cycle 1 Day 2 until discontinuation. Capivasertib will be administrated in both Part A and Part B.
Study NCT04958226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Single doses of midazolam (syrup, 1 mg) will be given on cycle 1 Days 1, 8, and 12.
Study NCT06259890 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: measurement of salt intake
Description: measurement of salt intake without intervention
Study NCT04907045 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: The clinic is provided access to a health coach who conducts outreach with patients. The health coach facilitates engagement with the digital therapeutic and encourages contact with the care team.
Study NCT05771688 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FETO therapy
Description: placement of FETO prior to 29 weeks 6 days GA; and removal of the FETO device no later than 35 weeks and 6 days
Study NCT06395207 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Proactive community case management
Description: Community health workers conduct proactive visits to households in their community every two weeks for two months to screen for fever and test and treat febrile individuals for malaria.
Study NCT06395207 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Strengthened SBCC and stock out mitigation
Description: Ensure CHWs have all commodities needed for malaria testing and treatment and are adequately trained on SBCC messages to ensure activities are implemented as designed in the national strategy.
Study NCT04907045 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Practice Facilitation
Description: In the context of a supportive relationship, a trained facilitator delivers the following interventions to clinic staff: Bolster Education, Audit and Provide Feedback, Support Plan-Do-Study-Act Cycles, Engage Others in Change.
Study NCT04907045 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Implementation
Description: Brief clinician training and an implementation toolkit consisting of job aids, patient educational materials, scripted conversations, electronic health record tools, and a population management workbench.
Study NCT04808973 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir plus lamivudine in a FDC
Description: All participants will receive an ART regimen composed by Lamivudine plus Dolutegravir in a single pill (FDC)
Study NCT05299528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Direct Feedback
Description: Procedure-specific direct feedback will be provided to surgeon participants through electronic and written communication, on patients' opioid consumption-to-prescription ratio. Surgeon participants who perform more than 1 of the specified procedures will receive nudging communications for each individual procedure.
Study NCT04934059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yuxuebi tablet
Description: 0.5g/ tablet
Study NCT04934059 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: 0.5g/ tablet
Study NCT05963802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence (ChatGPT) Group
Description: Participants in Group A will be assigned to utilize ChatGPT as their tool to complete assignments. They will be given a period of six days to utilize artificial intelligence through ChatGPT for assignment completion. Along with the assignment instructions, participants will receive an ethical guideline and specific guidelines on how to effectively utilize ChatGPT. Once the intervention period is concluded, participants will be given a 24-hour window to complete a survey that assesses the usability of the technology. The survey aims to gather valuable feedback on the participants' experience and perception of using ChatGPT for their assignments. In addition, participants in Arm 1 will also be asked to fill out a survey regarding their perception of using artificial intelligence (AI) as an assistance tool to complete their assignments. This survey aims to gather insights into their thoughts, opinions, and attitudes towards utilizing AI in the learning process.
Study NCT06139302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: BI 1015550
Study NCT03975361 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Bliss-Believe
Description: The samples from the blood samples carried out within the framework of Bliss Believe will be collected for a biological collection. Only one sample of patients included in BLISS BELIEVE STUDY will be obtained during a standard of care visit. It will be 21ml of blood.
Study NCT04878809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Escola L'Horitzó
Description: Diagnosis of SARS-CoV-2 infection by rapid antigen detection tests in nasal and nasopharyngeal swabs, in asymptomatic and symptomatic subjects who attend regularly to L'Horitzó school .
Study NCT04878809 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Escola John Talabot
Description: John Talabot School will provide the incidence of infection by SARS-CoV-2 in order to compare the incidence of infection from L'Horitzó School.
Study NCT06455072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nituzumab
Description: EGFR monoclonal antibody
Study NCT06455072 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serplulimab
Description: PD-1 (programmed death receptor 1) monoclonal antibody
Study NCT05605158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone 30mg
Description: Pioglitazone 30 mg will be administered orally once daily for 24 weeks.
Study NCT05605158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 MG
Description: Empagliflozin 10 mg will be administered orally once daily for 24 weeks.
Study NCT06425289 — intervention group
Intervention type: OTHER
Intervention: Macrohemodynamic parameters
Description: Macrohemodynamic parameters will be estimated with transpulmonary thermodilution every 6 hours during the intervention period (5 days).~* Cardiac index~* Extravascular lung water index~* Pulmonary vascular permeability index~* Cardiac function index~* Global end-diastolic volume index~* Central venous pressure~* Fluid responsivness status (passive leg rising test)
Study NCT06509555 — intervention group
Intervention type: OTHER
Intervention: non-intervention
Description: non-intervention
Study NCT05198219 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ambu® aScope™ 4 Rhinolaryngo
Description: Patient indication following a rhinolaryngoscopy
Study NCT05198219 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional reusable rhinolaryngoscope
Description: Patient indication following a rhinolaryngoscopy
Study NCT05914532 — intervention group
Intervention type: OTHER
Intervention: lab testing
Description: Complete blood count and erythrocyte sedimentation rate and C-reactive protein values of the participants were analyzed by laboratory test.
Study NCT05702788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib hydrochloride tablets
Description: 75mg of Jaktinib administered orally Twice daily(BID) with best available treatment.
Study NCT05702788 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jaktinib hydrochloride tablets
Description: 100mg of Jaktinib administered orally Twice daily(BID) with best available treatment.
Study NCT05702788 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (given as two placebo tablets) administered orally BID with best available treatment.
Study NCT04759872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperinsulinemic-euglycemic Clamp
Description: Participants will be administered a constant-rate insulin infusion (to induce mild hyperinsulinemia), with an infusion of dextrose to maintain blood glucose concentration (to maintain euglycemia).
Study NCT05885074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin Arm
Description: The subject will be randomized, in a double-blind manner to Empagliflozin 25mg once daily for a period of 12 months
Study NCT05885074 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Arm
Description: The subject will be randomized, in a double-blind manner to receive placebo once daily for a period of 12 months
Study NCT05885074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise capacity VO2 maximum determination
Description: Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol and will also undergo a DEXA scan to determine the body mass.
Study NCT05885074 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise capacity VO2 maximum determination
Description: Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol and will also undergo a DEXA scan to determine the body mass.
Study NCT05885074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Challenge
Description: Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill and will also undergo a resting energy expenditure test.
Study NCT05885074 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Exercise Challenge
Description: Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill and will also undergo a resting energy expenditure test.
Study NCT04693507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teverelix TFA 120 mg
Description: Teverelix TFA 240 mg Day 0 and 120 mg every 6 weeks from week 6 to week 24
Study NCT04693507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teverelix TFA 180 mg
Description: Teverelix TFA 360 mg Day 0 and 180 mg every 6 weeks from week 6 to week 24
Study NCT04901494 — intervention group
Intervention type: DRUG
Intervention: SSRI
Description: Selective serotonin reuptake inhibitor
Study NCT04976946 — intervention group
Intervention type: OTHER
Intervention: Comprehensive questionnaire
Description: Multi-staged, international Delphi study that aims to establish criteria for standardised complication reporting in Urology.
Study NCT05298540 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based computerised cognitive training with BrainHQ
Description: Participants will be registered for individual accounts to an online CCT program created by BrainHQ (Posit Science, San Francisco), that can be administered using their own computer or tablet. BrainHQ has been associated with improvements in memory, attention, and processing speed. The program will be customised to target domains thought to be deficient in the postoperative period and will include training in memory, attention, and processing speed. Specifically, the following six games have been selected: hear, hear (auditory memory and attention), to-do list training (working memory), divided attention (attention), target tracker (attention), double decision (useful field of view and visual processing speed), and eye for detail (visual processing speed and visual working memory). The exercises are adaptive, adjusting the application difficulty to the participants performance.
Study NCT01564472 — intervention group
Intervention type: OTHER
Intervention: PSG Scoring
Description: No participants will be enrolled and no interventions, besides PSG scoring will be utilized.
Study NCT05036291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NB004 tablets
Description: Part1: Dose escalation phase of study drug NB004 monotherapy:~Drug: NB004 tablets~NB004 tablets will be administered orally once daily for repeated 28-day cycles until discontinuation criteria are met.~Part 2: Dose Escalation Phase/ COMBO Dose Expansion Phase for the NB004 in combination with Sotorasib:~Drug: NB004 tablets \& Sotorasib~NB004 tablets will be administered orally once a daily for repeated 21-day cycles until discontinuation criteria are met.~Sotorasib will be administered with the recommended dosage per prescribing information approved by the FDA~Part 3: Dose Escalation Phase/ COMBO Dose Expansion Phase for the NB004 in combination with Sotorasib:~Drug: NB004 tablets \& Sotorasib~NB004 tablets will be administered orally once daily for repeated 21-day cycles until discontinuation criteria are met.~Sotorasib will be administered with the recommended dosage per prescribing information approved by the FDA .
Study NCT04708002 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: early integrated palliative approach model
Description: From the construction of a common vision of palliative care between actors inside and outside the nursing home to the sustainability of palliative care in nursing home.
Study NCT06342596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-LY3473329
Description: Administered orally
Study NCT06342596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]-LY3473329
Description: Administered IV
Study NCT06342596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3473329
Description: Administered orally